Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Revenue projections:

Revenue projections for DXCM
Revenue projections for DXCM

DXCM's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 1.883000
forwardPE 19.890444
debtToEquity 50.852000
earningsGrowth 0.780000
revenueGrowth 0.131000
grossMargins 0.601010
operatingMargins 0.256430
trailingEps 2.330000
forwardEps 2.993900

DXCM's current ratio of 1.883 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects DXCM's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
DXCM's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
Positive earnings and revenue growth for DexCom, Inc. suggest that the company is expected to grow its business. This trend reflects strong financial performance, with continued profitability and sales increases indicating a bright outlook for future expansion.
Positive gross and operating margins for DXCM highlight the company's profitability. These metrics reflect DXCM's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
DexCom, Inc.'s forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting DexCom, Inc. to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for DXCM
Price projections for DXCM

The present price of DXCM in relation to its projections indicates a lack of clear risks or opportunities. This balanced situation suggests that investors may find it prudent to wait for further signals before making significant moves in the stock.

Insider Transactions:

Insider Transactions for DXCM
Insider Transactions for DXCM


19 sales transactions of DXCM were conducted, with market price at 74.07921098407947.DXCM had 1 buy transactions while market price was at 54.84000015258789 per share.No clear trend can be drawn from the insider transactions, leaving the company's next steps and outlook uncertain from this data alone.

Recommendation changes over time:

Recommendations trend for DXCM
Recommendations trend for DXCM


The recent buy bias from analysts suggests DXCM is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, DXCM appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.